European Rare Diseases Research Alliance – ERDERA
ERDERA Joint Transnational Call 2027
ERDERA Joint Transnational Calls supports interdisciplinary research to address identified gaps. These calls foster cross-border collaboration and align with the strategic priorities of the rare disease community.
ERDERA’s 2027 Joint Transnational Call, “Catalysing Collaborative Research for Recently Identified Rare Diseases”, is expected to open on 1 December 2026. Read the pre-announcement here.
The call aims to support collaborative research into recently identified rare diseases that remain poorly understood, helping to build the knowledge base needed for future therapeutic development.
An information webinar for potential applicants is planned for 14 December 2026, 15:00–16:00 CET. Register for the information webinar.
ERDERA Clinical Trials Call
ERDERA has opened the first ERDERA Clinical Trials Call (ECTC) to support multinational, GCP‑compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases. Priority areas: paediatric rare diseases; rapidly progressive rare diseases; and rare diseases with no approved therapeutic options or with substantial residual unmet medical need despite existing treatments.
Stage 0 – EOI (mandatory): 1 July – 10 September 2026.
Stage 1 – Short Proposal: 15 September – 29 October 2026.
ERDERA Networking Support Scheme
A competitive funding instrument for networking events to share knowledge on rare diseases and rare cancers
Through this constantly open call, ERDERA supports the organisation of transnational networking events that promote knowledge sharing, research uptake and collaborations among clinicians, researchers, and patients/patient advocacy organizations (PAOs).
These events will strengthen new or expanding research networks on rare diseases and rare cancers in general and promote the inclusion of typically underrepresented countries (UCs) in European rare diseases and rare cancers networks in particular.
With funding of up to €30 000 per networking event, the scheme has been open since May 2025, offering a flexible framework for building the connections essential to meaningful knowledge sharing in rare disease and rare cancers research.
Innovative Health Initiative – IHI
IHI Call 13
IHI call 13 is a two-stage call with topics on accelerating healthcare innovation through networks, reducing animal use in drug safety studies, and decoding the immuno-science of diseases affected by ageing and the immune system.
Topics
Topic 1: A network to boost the next wave of European innovations in healthcare
Topic 3: Decode the immuno-science of age-related immune-mediated diseases
Key deadlines
Short proposal submission deadline: 08 October 2026 at 17:00 Brussels time
Full proposal submission deadline: 21 April 2027 at 17:00 Brussels time
IHI Call 14
The following topics are under consideration for inclusion in IHI calls 14 and 15, which are planned for launch in early 2027.
IHI call 14 draft topic texts
- Topic 1: Validation of human-relevant novel approaches to accelerate the discovery and pre-clinical development of innovative medicinal products and health technologies
- Topic 2: Validated, predictive approaches for clinical development of innovative personalised health technologies
- Topic 3: Transforming healthcare delivery through integrated, scalable and patient-centred care systems
- Topic 4: Advanced therapy medicinal products: Supporting manufacturing and clinical centre readiness in Europe
IHI call 15 draft topic texts
Topic 1: A common European approach to equitable patient access to compassionate use
European Partnership for Personalised Medicine – EP PerMed
EP PerMed Joint Transnational Call (JTC) 2027 – Pre-announcement
The European Partnership for Personalised Medicine (EP PerMed) is launching the Joint Transnational Call 2027 for Cell and Gene Therapy for Personalised Medicine (CGT4PM2027).
The call will be implemented in two stages, i.e. a pre- and a full proposal phase.
Proposals must focus on the development and validation of an innovative and novel Cell and Gene Therapy for Personalised Medicine.
At least one of the following approaches must be employed:
- Somatic cell therapeutics;
- Gene therapeutics;
- Combined cell- and gene therapeutics;
- Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure.
Expected timeline
Publication of the call: 04 November 2026
Information day: 03 December 2026
Deadline for pre-proposal submission: 20 January 2027 (14:00, CET)
Deadline for full proposal submission: 25 May 2027 (14:00, CEST)
Transforming Health and Care Systems – THCS
THCS JTC 2027 – Pre-announcement
Pre-announcement of Joint Transnational Call for proposals “Transforming the Health and Care Workforce for Sustainable and Resilient Systems”.
THCS will launch its fifth Joint Transnational Call for proposals aiming to support implementation-oriented research and innovation that accelerates the uptake, adaptation, testing, evaluation and scaling of evidence-informed approaches to health and care workforce transformation.
Expected timeline
Publication of the call: 16 November 2026
Information Webinar: 02 December 2026 – 14:30-16:30 CET
Deadline for pre-proposal submission: 21 January 2027 (14:00, CET)
Deadline for full proposal submission: 24 June 2027 (14:00, CEST)
Calls of the European Commission
Please find here the links to calls of the European Commission you can apply to:
HORIZON EUROPE Work Programme
Funding opportunities under Horizon Europe are set out in multiannual work programmes. The Work programme addressing Health is the work programme – cluster 1. The aim of cluster 1 include improving and protecting the health and well-being of citizens of all ages by generating new knowledge, developing innovative solutions and integrating where relevant a gender perspective to prevent, diagnose, monitor, treat and cure diseases.